Active, Not RecruitingPhase 1psilocybin

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder

NCT ID

NCT05322954

Target Enrollment

12 participants

Start Date

2023-03-03

Est. Completion

2026-05

About This Study

The purpose of this research study is to investigate the safety and feasibility of two (2) oral doses of psilocybin when combined with behavioral support for methamphetamine use disorder (MUD). Participants have a diagnosis of methamphetamine use disorder (MUD). Participants can expect to be actively engaged in the study for up to 26 weeks.

Conditions Studied

Methamphetamine Use DisorderSubstance-Related DisordersChemically-Induced DisordersSubstance Use DisordersStimulant-Use Disorder

Interventions

•Psilocybin

Eligibility

Age:25 Years - 65 Years

Healthy Volunteers:No

View full eligibility criteria

Inclusion Criteria:

* Diagnosis of methamphetamine use disorder

Exclusion Criteria:

* Positive urine pregnancy at any time point during screening or study participation
* Inadequately treated hypertension, defined as 2 blood pressure readings, 10 minutes apart, of greater than 140/90 mmHg systolic/diastolic
* Current acute coronary syndrome or angina
* History of heart transplant or stroke
* Current use of and inability or unwillingness to taper off of medications that may interact with psilocybin
* Current insulin dependence, due to Type I or Type II diabetes

Study Locations (1)

University of Wisconsin